Celltrion Pharm Inc (068760) - Net Assets

Latest as of September 2025: ₩426.42 Billion KRW ≈ $288.98 Million USD

Based on the latest financial reports, Celltrion Pharm Inc (068760) has net assets worth ₩426.42 Billion KRW (≈ $288.98 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩745.80 Billion ≈ $505.42 Million USD) and total liabilities (₩319.38 Billion ≈ $216.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Celltrion Pharm Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩426.42 Billion
% of Total Assets	57.18%
Annual Growth Rate	9.08%
5-Year Change	32.06%
10-Year Change	68.02%
Growth Volatility	14.65

Celltrion Pharm Inc - Net Assets Trend (2011–2024)

This chart illustrates how Celltrion Pharm Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Celltrion Pharm Inc for the complete picture of this company's asset base.

Annual Net Assets for Celltrion Pharm Inc (2011–2024)

The table below shows the annual net assets of Celltrion Pharm Inc from 2011 to 2024. For live valuation and market cap data, see 068760 company net worth.

Year	Net Assets	Change
2024-12-31	₩396.92 Billion ≈ $268.99 Million	+5.38%
2023-12-31	₩376.67 Billion ≈ $255.26 Million	+5.57%
2022-12-31	₩356.79 Billion ≈ $241.79 Million	+7.48%
2021-12-31	₩331.97 Billion ≈ $224.97 Million	+10.45%
2020-12-31	₩300.56 Billion ≈ $203.69 Million	+7.33%
2019-12-31	₩280.03 Billion ≈ $189.77 Million	+3.70%
2018-12-31	₩270.03 Billion ≈ $183.00 Million	-8.03%
2017-12-31	₩293.62 Billion ≈ $198.98 Million	-14.80%
2016-12-31	₩344.65 Billion ≈ $233.56 Million	+45.89%
2015-12-31	₩236.23 Billion ≈ $160.09 Million	+10.17%
2014-12-31	₩214.43 Billion ≈ $145.31 Million	+27.32%
2013-12-31	₩168.41 Billion ≈ $114.13 Million	+7.10%
2012-12-31	₩157.25 Billion ≈ $106.56 Million	+22.59%
2011-12-31	₩128.27 Billion ≈ $86.93 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Celltrion Pharm Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 13250487089000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	₩132.50 Billion	33.38%
Common Stock	₩272.35 Billion	68.62%
Total Equity	₩396.92 Billion	100.00%

Celltrion Pharm Inc Competitors by Market Cap

The table below lists competitors of Celltrion Pharm Inc ranked by their market capitalization.

Company	Market Cap
Mister Car Wash, Inc. Common Stock NYSE:MCW	$1.65 Billion
Visionox Technology Inc SHE:002387	$1.65 Billion
Cofco Biochemical Anhui Co Ltd SHE:000930	$1.65 Billion
Kraken Robotics Inc V:PNG	$1.65 Billion
Collective Mining Ltd TO:CNL	$1.65 Billion
China Security & Fire Co Ltd Class A SHG:600654	$1.65 Billion
Fagron NV BR:FAGR	$1.65 Billion
Jiangsu Jiangyin Rural Commercial Bank Co Ltd SHE:002807	$1.65 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Celltrion Pharm Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 376,665,735,600 to 396,921,557,130, a change of 20,255,821,530 (5.4%).
Net income of 21,966,117,520 contributed positively to equity growth.
Share repurchases of 4,047,083,050 reduced equity.
New share issuances of 880,837,380 increased equity.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩21.97 Billion	+5.53%
Share Repurchases	₩4.05 Billion	-1.02%
Share Issuances	₩880.84 Million	+0.22%
Other Changes	₩1.46 Billion	+0.37%
Total Change	₩-	5.38%

Book Value vs Market Value Analysis

This analysis compares Celltrion Pharm Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 6.14x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩9217.14	₩56100.00	x
2017-12-31	₩7829.62	₩56100.00	x
2018-12-31	₩7190.64	₩56100.00	x
2019-12-31	₩7451.76	₩56100.00	x
2020-12-31	₩7997.82	₩56100.00	x
2021-12-31	₩8415.26	₩56100.00	x
2022-12-31	₩8201.30	₩56100.00	x
2023-12-31	₩8661.73	₩56100.00	x
2024-12-31	₩9132.28	₩56100.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Celltrion Pharm Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 5.53%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 4.60%
• Asset Turnover: 0.71x
• Equity Multiplier: 1.69x
Recent ROE (5.53%) is above the historical average (3.52%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	2.68%	7.39%	0.22x	1.68x	₩-9.39 Billion
2012	2.26%	7.56%	0.14x	2.11x	₩-12.17 Billion
2013	1.55%	4.96%	0.15x	2.15x	₩-14.23 Billion
2014	2.74%	8.79%	0.16x	1.92x	₩-15.57 Billion
2015	2.85%	9.01%	0.16x	1.98x	₩-16.89 Billion
2016	0.85%	2.78%	0.21x	1.48x	₩-31.55 Billion
2017	0.92%	2.00%	0.29x	1.60x	₩-26.65 Billion
2018	-3.48%	-6.39%	0.32x	1.68x	₩-36.39 Billion
2019	3.07%	4.96%	0.37x	1.68x	₩-19.40 Billion
2020	6.97%	8.97%	0.43x	1.82x	₩-9.12 Billion
2021	10.42%	8.67%	0.63x	1.92x	₩1.38 Billion
2022	7.28%	6.72%	0.64x	1.68x	₩-9.72 Billion
2023	5.65%	5.47%	0.61x	1.70x	₩-16.40 Billion
2024	5.53%	4.60%	0.71x	1.69x	₩-17.73 Billion

Industry Comparison

This section compares Celltrion Pharm Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $417,135,058,503
Average return on equity (ROE) among peers: 2.50%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Celltrion Pharm Inc (068760)	₩426.42 Billion	2.68%	0.75x	$1.65 Billion
Dongwha Pharm.Co.Ltd (000020)	$296.94 Billion	15.83%	0.24x	$113.83 Million
Yuhan Corp. (000100)	$756.45 Billion	11.87%	0.32x	$4.57 Billion
Yuhan Corp Preferred (000105)	$1.61 Trillion	6.79%	0.30x	$59.61 Million
Yuyu Pharma (000220)	$73.73 Billion	-0.34%	0.41x	$46.55 Million
Yuyu Pharma Inc (000225)	$123.37 Billion	-4.85%	0.58x	$17.67 Million
Yuyu Pharma Inc (000227)	$71.49 Billion	-10.45%	0.42x	$42.93 Million
Ildong Holdings Co Ltd (000230)	$164.95 Billion	-2.25%	0.61x	$76.14 Million
Samil Pharm (000520)	$65.75 Billion	-8.13%	2.44x	$127.90 Million
Donga Socio Holdings (000640)	$746.90 Billion	2.65%	0.82x	$427.15 Million
Jw Pharmac (001060)	$265.44 Billion	13.94%	1.43x	$476.78 Million

About Celltrion Pharm Inc

KQ:068760 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$1.65 Billion

₩2.44 Trillion KRW

Market Cap Rank

#6984 Global

#194 in Korea

Share Price

₩56100.00

Change (1 day)

-2.77%

52-Week Range

₩46200.00 - ₩75700.00

All Time High

₩222138.48